Target Indications definition

Target Indications means […***…].
Target Indications means (a) the treatment of the neuregulin 1 gene (NRG1) fusion-positive non-small cell lung cancer, (b) the treatment of the neuregulin 1 gene (NRG1) fusion-positive pancreatic cancer ((a) and (b) collectively, the “Existing Target Indications”), and (c) the treatment of any other tumor type or tissue agnostic treatment of neuregulin 1 gene (NRG1) fusion-positive cancer or tumor, irrespective of line of treatment.
Target Indications shall have the meaning assigned to such term in Section 2.1(c).

Examples of Target Indications in a sentence

  • Company shall keep Merus reasonably informed of the plans for, and the status, progress and results of, all Development and regulatory activities related to the Licensed Compound, Licensed Products or any Clinical Trials conducted by or on behalf of Company or any of its Affiliates or Sublicensees, including seeking to expand the Indication for which a Licensed Product is used beyond approval in the Existing Target Indications or earlier lines of therapy or in combination.

  • Gilead shall use Commercially Reasonable Efforts to Commercialize the first Licensed Product in each of the Major Markets in the Licensed Territory for each of the Target Indications.

  • During the Discovery Term for each Collaboration Target and the Discovery Program that is directed to such Collaboration Target, the Discovery Plan shall specify that the primary Target Indication for such Collaboration Target, and the Discovery Program shall be in the Oncology Field (it being understood that after the Discovery Term, the Development Plan for any Licensed Program may specify other Target Indications outside of the Oncology Field).

  • The Parties acknowledge and agree that each Program shall initially be directed towards Target Indications in the Oncology Field.

  • Company shall use Commercially Reasonable Efforts to (a) obtain and maintain Regulatory Approval for the Licensed Product in the Target Indications in the Territory, (b) following receipt of any Regulatory Approval for the Licensed Product in the Territory, Commercialize the Licensed Product in the Field in the Territory for each indication in the Field for which Regulatory Approval has been obtained in the Territory, and (c) maximize Net Sales of the Licensed Products in the Field in the Territory.

  • The Parties shall discuss the OSA Proposal in good faith and, if the Parties mutually agree upon a go-to-market Commercialization plan for the OSA Target Indications (whether incorporating, in whole or in part, the elements of the OSA Proposal or otherwise), the Initial Commercialization Plan shall be amended by mutual written agreement of the Parties to reflect such mutually agreed upon go-to-market Commercialization plan.

  • Gilead shall be primarily responsible for Development and seeking Regulatory Approval of the Licensed Product and Gilead Combination Products in the Territory and shall use Commercially Reasonable Efforts with respect thereto for the first Licensed Product in each of the Major Markets in each of the Target Indications.

  • In the event Takeda terminates an Initial Program in accordance with Section 5.3 (each, a “Terminated Initial Program”), Takeda will have the right to initiate, during the Exclusivity Period, an Additional Program for one of the Indications that Takeda elects from the Reserved Target Indications (“Additional Indication”).

  • Gilead shall use Commercially Reasonable Efforts to Commercialize the first Licensed Product in each of the Major Markets for each of the Target Indications.

  • For the avoidance of doubt, the scope of each Development Program of a Product shall at all times be limited to the Target Indications applicable to such Product and shall not extend to any other indication unless such indication becomes a Target Indication pursuant to Section 2.12.


More Definitions of Target Indications

Target Indications means the treatment or prevention of (a) Narcolepsy, including treatment of Cataplexy (“Narcolepsy with Cataplexy” or Type 1); (b) excessive daytime sleepiness (“EDS” or Type 2); (c) obstructive sleep apnea (“OSA”); and (d) idiopathic hypersomnia (“IH”).
Target Indications means the following Respiratory Indications: [***].
Target Indications means the diagnosis, therapeutic treatment and/or prevention of narcolepsy (including Type 1 (with cataplexy) and Type 2 and the sleepiness associated therewith) [***], and (b) any other Additional Indication(s) added to this Agreement pursuant to Section 4.3.
Target Indications means the following Respiratory Indications: Respiratory Distress Syndrome (RDS); Chronic Lung Disease (BPD); Transient Tachypnea; Hypoxemia; Pulmonary Hypertension; Pneumonia; Bronchiolitis; Diaphragmatic Hernia; Acute Lung Injury (ALI); Acute Respiratory Distress Syndrome (ARDS); Lung Transplantation; Respiratory Syncitial Virus (RSV); and, Cystic Fibrosis.
Target Indications means the diagnosis, therapeutic treatment and/or prevention of narcolepsy (including Type 1 (with cataplexy) and Type 2 and the sleepiness associated therewith) [***], and (b) any other Additional Indication(s) added to this Agreement pursuant to Section 4.3. ​ ​